Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 05.

318P - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Date

03 Dec 2022

Session

Poster viewing 05.

Presenters

Miranda Gogishvili

Citation

Annals of Oncology (2022) 33 (suppl_9): S1560-S1597. 10.1016/annonc/annonc1134

Authors

M. Gogishvili1, T. Melkadze2, T. Makharadze3, D. Giorgadze4, M. Dvorkin5, K.D. Penkov6, K. Laktionov7, G. Nemsadze8, M. Nechaeva9, I. Rozhkova10, E. Kalinka11, C. Gessner12, B. Moreno Jaime13, R. Passalacqua14, S. Li15, K. McGuire15, R.G. Quek16, G. Gullo16, P. Rietschel16

Author affiliations

  • 1 Oncology Department, High Technology Medical Centre, University Clinic Ltd, 0144 - Tbilisi/GE
  • 2 Oncology Department, Academician F. Todua Medical Center, 0112 - Tbilisi/GE
  • 3 Medical Oncology, LTD High Technology Hospital Med Center, 0168 - Tbilisi/GE
  • 4 Oncological Concilium Group, Oncological Concilium Group, David Tvildiani Medical University, 0168 - Tbilisi/GE
  • 5 Oncology, State Budgetary Healthcare Institution of Omsk Region, 644013 - Omsk/RU
  • 6 General Department, Private Medical Institution Euromedservice, 196603 - St Petersburg/RU
  • 7 Oncology, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center Of Oncology”, Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), 115478 - Moscow/RU
  • 8 Tbilisi Cancer Center, The Institute of Clinical Oncology, 0159 - Tbilisi/GE
  • 9 Chemotherapy, Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk/RU
  • 10 Oncology, State Budgetary Healthcare Institution of Kaluga Region, 248023 - Kaluga/RU
  • 11 Research Lnstitute, Polish Mother’s Memorial Hospital, 93-513 - Łódź/PL
  • 12 N/a, POIS Leipzig GbR Steffi Geßner, 04357 - Leipzig/DE
  • 13 Department Of Oncology, Hospital Regional ISSSTE, Leon/MX
  • 14 Oncology Dept., Istituti Ospitalieri Di Cremona, 26100 - Cremona/IT
  • 15 Clinical Sciences, Oncology, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
  • 16 Clinical Sciences, Oncology, Regeneron Pharmaceuticals, Inc., Tarrytown/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 318P

Background

EMPOWER-Lung 3 is a randomised, 2-part, Phase 3 study of 1L treatment of patients (pts) with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC without actionable mutations (NCT03409614). The double-blind Part 2 of the study enrolled pts irrespective of PD-L1 levels and compared clinical activity and safety of cemiplimab, an anti-PD-1, plus (+) platinum-based chemo, versus (vs) placebo (PBO)+chemo.

Methods

Pts were randomised (2:1; stratified by histology and PD-L1 expression) to receive cemiplimab 350 mg once every 3 weeks (Q3W) or PBO Q3W for 108 weeks (or until progression), plus up to 4 cycles of chemo (followed by mandatory pemetrexed maintenance for NSQ pts assigned to a pemetrexed-containing regimen). Primary endpoint was overall survival (OS). Key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR) per blinded independent central review. Here we report Part 2 results from the prespecified 2 interim analysis. Data cut-off was 14 June 2021.

Results

Overall, 466 pts were eligible and randomised to cemiplimab+chemo (n=312) or PBO+chemo (n=154). Median (range) age was 63.0 (25-84) years; 57.1% had NSQ NSCLC; and 85.2% had Stage IV disease. Median OS was 21.9 months with cemiplimab+chemo vs 13.0 months with PBO+chemo (HR, 0.71; P=0.014). Cemiplimab+chemo was associated with superior median PFS (8.2 vs 5.0 months; HR, 0.56), higher ORR (43.3% vs 22.7%), and longer median duration of response (DOR) (15.6 months vs 7.3 months) vs PBO+chemo (Table). Incidence of Grade ≥3 adverse events was 43.6% in cemiplimab+chemo arm and 31.4% in PBO+chemo arm. Table: 318P

Cemiplimab+chemo (n=312) PBO+chemo (n=154)
Duration of follow-up, median (IQR), months 16.3 (13.9–19.1) 16.7 (14.2–19.0)
OS, median (95% CI), months 21.9 (15.5–NE) 13.0 (11.9–16.1)
HR (95% CI) 0.71 (0.53–0.93); P=0.014
PFS, median (95% CI), months 8.2 (6.4–9.3) 5.0 (4.3–6.2)
HR (95% CI) 0.56 (0.44–0.70); P<0.0001
ORR, % (95% CI) 43.3 (37.7–49.0) 22.7 (16.4–30.2)
Odds ratio (95% CI) 2.68 (1.72–4.19); P<0.0001
Complete response, n (%) 8 (2.6) 0 (0)
Partial response, n (%) 127 (40.7) 35 (22.7)
Kaplan-Meier estimated DOR, median (95% CI), months 15.6 (12.4–NE) 7.3 (4.3–12.6)

Conclusions

In pts with advanced NSCLC, 1L cemiplimab+chemo demonstrated clinically meaningful and statistically significant improvement in OS, PFS, ORR and DOR vs chemo alone, with a safety profile consistent with cemiplimab monotherapy and platinum-based chemo.

Clinical trial identification

NCT03409614.

Editorial acknowledgement

Medical writing support was provided by Jenna Lee, MS of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.

Legal entity responsible for the study

Regeneron Pharmaceuticals, Inc., and Sanofi.

Funding

Regeneron Pharmaceuticals, Inc., and Sanofi.

Disclosure

K.D. Penkov: Financial Interests, Personal, Advisory Role: AstraZeneca, Merck Sharp & Dohme, Nektar, Pfizer, Regeneron Pharmaceuticals, Inc., and Roche. E. Kalinka: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Nektar, Pfizer, Roche, and Regeneron Pharmaceuticals, Inc. C. Gessner: Financial Interests, Personal, Advisory Board: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi. R. Passalacqua: Financial Interests, Personal, Advisory Board: Astellas, Bristol Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Roche, and Sanofi-Aventis; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Novartis, and Pierre-Fabre. S. Li, K. McGuire, R.G. Quek, G. Gullo, P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.